Zhihao Peter Qiu

FDA investigator

Appears on 5 documents from 2013 to 2021, most often at sites in Japan. Most often cites production record review (21 CFR 211.192).

5
Documents on file
6.4
Observations per 483
2013
First seen
2021
Most recent

What they cite most

From 32 observations

Activity by year

2013: 1, 2019: 1, 2020: 1, 2021: 2

Where

Japan 1 · Maryland 1 · North Carolina 1 · Rhode Island 1 · Singapore 1

Often inspects with

Bo Chi· Donald Obenhuber· Jacek Cieslak

Is Zhihao Peter Qiu coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

5 documents, newest first
FirmOpen
483 MSD International GmbH (Singapore Branch)Sep 3, 2021 · Singapore, Singapore
483 Fujifilm Diosynth Biotechnologies USA, Inc.Apr 21, 2021 · Morrisville, North Carolina
483 Chugai Pharma Manufacturing Co., LtdFeb 21, 2020 · Utsunomiya, Japan
483 Immunex Rhode Island CorporationApr 19, 2019 · West Greenwich, Rhode Island
483 Human Genome Sciences, Inc.Apr 26, 2013 · Rockville, Maryland

About this profile

What does Zhihao Peter Qiu inspect?

Zhihao Peter Qiu appears on 5 documents on file covering 5 sites, most often in Japan.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.100 and 21 CFR 211.113.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Zhihao Peter Qiu is dated Sep 3, 2021.